<DOC>
	<DOCNO>NCT02146508</DOCNO>
	<brief_summary>Esophageal cancer common Kenya . The precursor esophageal cancer esophageal squamous dysplasia ( ESD ) . In study , person know ESD undergo endoscopic removal ablation ESD order prevent development esophageal cancer .</brief_summary>
	<brief_title>Endoscopic Prevention Esophageal Cancer Tenwek Hospital</brief_title>
	<detailed_description>Esophageal squamous dysplasia ( ESD ) precursor lesion esophageal squamous cell cancer . ESD cause symptom detect screen . ESD may harbor various grade dysplasia . Patients moderate grade high grade dysplasia ( MGD HGD ) 40-fold increased risk esophageal squamous cell cancer . In study , person know ESD MGD HGD basis prior screen invite undergo endoscopic treatment either endoscopic mucosal resection ( EMR ) and/or radio frequency ablation ( RFA ) order remove ablate region ESD . Participants undergo series endoscopy treat ESD monitor success treatment .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Participant 1885 year age , inclusive Participant prior endoscopy Lugol 's chromoendoscopy demonstrating unstained lesion ( USL ) least 5 mm biopsy contain moderate grade dysplasia ( MGD ) , high grade dysplasia ( HGD ) , esophageal squamous cell cancer ( ESCC ) flat mucosa limit lamina propria , evidence invasion . The maximum allowable linear length USLbearing esophagus 20 cm . No 14 continuous linear cm esophagus require treatment MGD , HGD , ESCC . For patient ESCC , CT scan chest upper third abdomen show exclusionary finding trial , metastasis . Participant pregnant plan become pregnant ensue 12 month ( confirmation pregnancy status woman childbearing age ability require prior endoscopy urine blood test , subject believe may pregnant missed menstrual period ) Participant eligible treatment followup endoscopy biopsy require protocol Participant willing provide write , inform consent participate clinical study understand responsibility trial participation Esophageal stricture prevent passage therapeutic endoscope Any prior endoscopic resection Any esophageal dilation past 12 month Any history ESCC esophagus , except ESCC flat mucosa limit lamina propria diagnose within 12 month study enrollment . In participant ESCC , evidence nodal involvement distant metastases Any previous ablative therapy within esophagus ( photodynamic therapy , multipolar electrical coagulation , argon plasma coagulation , laser treatment , ) radiation therapy esophagus . Any previous esophageal surgery , except fundoplication Evidence esophageal varix detect within last 6 month initial EMR/RFA procedure Evidence eosinophilic esophagitis endoscopy and/or histology History coagulopathy , use warfarin within past month . Report uncontrolled coagulopathy international normalize ratio ( INR ) &gt; 2 platelet count &lt; 75,000 platelet per ÂµL ( note : laboratory test require subject study ) Participant use aspirin , clopidogrel , nonsteroidal antiinflammatory drug discontinue 7 day therapeutic session Participant know history unresolved drug alcohol dependency would limit ability comprehend follow instruction relate informed consent , posttreatment instruction , followup guideline Participant implantable pacing device ( example ; automatic implantable cardioverter/defibrillator , neurostimulator , cardiac pacemaker ) receive clearance enrollment study physician responsible pace device Participant suffers psychiatric illness deem investigator inability comply protocol Participant life expectancy le 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Radiofrequency , catheter ablation</keyword>
	<keyword>Endoscopic mucosal resection</keyword>
	<keyword>Esophageal squamous dysplasia</keyword>
	<keyword>Cancer prevention</keyword>
</DOC>